THE GLOBAL COMMERCIAL ARM OF YIFAN

CORPORATE PRESENTATION 2020

YIFAN

SciGen

BIOTON

fisiopharma

EVIVE BIOTECH

CONTENT

01

Yifan Group & Companies

YIFAN at a glance

3 billion
recent market cap

$710 million (+13%)
2019 global revenues

#1 vitamin B5 supplier, with >50% of the global market

~6,000
employees worldwide

~20 manufacturing sites around the world

~6 regional headquarters in Asia, US and Europe

has evolved into a global pharmaceutical company with strong commercial presence across many regions

Portfolio includes **specialty products, biosimilars**, generics (solids and injectables) and diagnostics.

Existing capabilities include **R&D** (small molecules and biologics), **manufacturing** (API and FDF), sales and marketing.

Innovative biotech R&D includes late stage asset (G-CSF), **early stage asset** for autoimmune diseases and **technology platform** for CD3 T-cell engaging bi-specific antibodies (BsAbs).

Global Pharmaceutical company with worldwide distribution rights.

Commercial arm of YIFAN, responsible for commercialization.

Biotechnology RHI (API and finished forms), manufacturing and R&D for Analogs in Poland (EU).

High quality, EU based CDMO for injectables

Biotechnology arm with US assets

SciGen

Commercial arm dedicated to deliver high quality healthcare solutions worldwide





Licensing and commercializing biotech products for worldwide distribution.

BIOTON

Develops and manufactures human insulin and insulin analogs

- Facility is **GMP-compliant** and approved in European Union
- **Positive audits** from Big Pharma, and Health Regulatory Agencies (e.g. ANVISA)
- Quality Control and Quality Assurance designed to meet **EMA requirements.**
- **R&D team** with bioengineering, analytical labs and lab scale manufacturing plants
- **Full cycle of insulin production** from biosynthesis to packaging (cartridges and vials)

Develops and manufactures injectable pharmaceutical products

Development and production of injectables

A fully owned subsidiary of Yifan Pharmaceuticals.



Development and production of injectable pharmaceutical products, with the authorization to manufacture **sterile drugs, precursors, corticosteroids and narcotics.**

3 manufacturing lines (filling), 2 visual inspection machines **US FDA/EU approved.**

EVIVE BIOTECH

Biotechnology arm of Yifan with US Assets and an experienced leadership team

Leadership formerly

from Amgen, Sanofi, Novartis, FDA, Eli Lilly, Daiichi Sankyo, Imclone

Innovative pipeline

First-in-class and best-in-class drug development programs from discovery through global Phase III

Global reach

R&D center in Shanghai, drug substance cGMP facility in Beijing, Regulatory in the US with CRO1s and DP2 CMO supporting globally

Asset	Indication	Pre-clin[4]	IND[5]	PI	PII	PIII
DiKine™: Dimeric Cytokine Platform						
F-627 (G-CSF Dimer)	Chemo Induced Neutropenia (US/EU)	●	●	●	●	●
	Chemo Induced Neutropenia (CN)	●	●	●	●	●
F-652 (IL-22 Dimer)	Graft vs Host Disease (US)	●	●	●	●	
	Acute Alcoholic Hepatitis (US)	●	●	●	●	
	Acute Pancreatitis (CN)	●	●	●		
ITab™: ImmunoTherapy Antibody Platform						
A-329	CD19 (bivalent), B Cell Lymphoma	●	●	●		
A-337	EpCAM, Solid tumors	●	●			
A-319	CD19 (monovalent), B Cell Leukemia	●				

Notes: 1) Granulocyte-Colony Simulating Factor; 2) Chemotherapy Induced Neutropenia; 3) Graft vs Host Disease; 4) Pre-clinical; 5) Investigational New drug

02

Our Global Partners

Our Global Partners

Roche

NOVARTIS

SANDOZ
a Novartis company

LG

mayne pharma

FRESENIUS KABI

Glenmark
A new way for a new world

IPSEN
Innovation for patient care

INTAS

Bel Teca, Inc.

TEIKOKU SEIYAKU CO.,LTD.

CHEPLA PHARM
Arzneimittel

Partnering initiatives focus on inward and outward transactions, for small and large molecules, covering mature and developing markets

Inward

China

Originator brands
Hard-to-make products

International Sector

Oncology, Endocrinology

Product licensing

Brand acquisition

Outward

Commercialization

Mature markets

Co-development

Japan

Biotech out-licensing

Innovative, biosimilars

Strategic

Geo-expansion

Market entry

Production

Capacity utilization

Portfolio, company acquisition

Dossier, CMO avenues

03

Product portfolio:

Endocrinology

GENSULIN®
SciLin™

High quality European human insulin with 20 years of experience confirms the products' effectiveness, safety and stability

Comes in Active Substance & Finished Form in 10 ml vials or 3 ml cartridges



Short-Acting
GENSULIN® R / SCILIN® R
(Regular human insulin, soluble)



Intermediate-Acting
GENSULIN® N / SCILIN® N
(NPH human insulin, isophane)



Premixed
GENSULIN® M30 / SCILIN® M30
(70% NPH & 30% short-acting human insulin)

GensuPen2
AN AUTOMATIC INSULIN PEN INJECTOR

Insulin Delivery Devices injectable pharmaceutical products

THOUSANDS OF SATISFIED PATIENTS WITH GENSUPEN® AROUND THE WORLD



- **GENSUPEN 2®**
  A new generation of Insulin pen devices
- Modern, automatic pen injectors with a dial-back mechanism
- Maximum dose 60IU, minimum increment 1IU

Automatic, low-force delivery system

Constant speed of the drug injection

A visible signal indicating end of the dose injection

Convenient emplacement of the trigger button

Automatic delivery of insulin, reducing the pain and risk of tissue traumatization, significantly improving convenience, providing patients with better metabolic control and satisfaction in their treatment.

Analog Pipeline

Development process ongoing for insulin technologies including: Advancing diabetes portfolio with new analog pipeline

Lispro
(rapid-acting insulin analog)

Glargine
(long-acting insulin analog)

Aspart
(rapid-acting insulin analog)

- **Commercial launch:** **From 2023 through 2025** starting with Lispro, followed by Glargine and Aspart
- **Global scope:** Process and clinical development programs along with **regulatory filings for US, EU** and **RoW** (ex. Japan)
- **Regulatory approach:** **BLA filing in US and MAA filing in EU** will be submitted at around the same time

SciTropin A™ (Somatropin)

Biosynthetic human Growth Hormone manufactured in Europe

SciTropin A™ is synthesized in E.coli cells that are identical to naturally occurring Human Growth Hormone suitable for:

Children

Growth disturbance due to insufficient secretion of growth hormone (growth hormone deficiency, GHD)

Adults

Replacement therapy in adults with pronounced growth hormone deficiency

- Manufactured by Sandoz in Schaftenau, Austria
- Currently marketed in:
  - Australia
  - Hong Kong
  - Korea
  - Malaysia
  - Philippines
  - Singapore
  - Vietnam

03

Product portfolio:
Oncology and Hepatology

ZOMETA®
zoledronic acid

Legacy of proven efficacy and safety for bone metastasis and hypercalcemia of malignancy

Zometa® has a legacy of proven efficacy and safety profile

Zometa® 4mg/100ml is a ready-to-use infusion, which is more convenient and accurate for HCPs

Indications

- Prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone or tumour-induced hypercalcaemia) in patients with advanced malignancies involving bone
- Treatment of hypercalcaemia of malignancy (HCM)

Currently marketed in APAC: Australia, Brunei, Hong Kong, Indonesia, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam.

Advancing a portfolio of innovative assets
addressing unmet medical needs

Asset	Overview	Recent Accomplishments	Upcoming Milestones
F-627	• Dimeric rh**G-CSF** fusion protein • Novel formulation to compete with Neulasta and biosimilars in the **$6bn global CIN market**	• **Global pivotal trial** positive read out May 2020 • Dec 2019, **China pivotal trial** successfully completed	• **US BLA filing** in Oct 2020 • China BLA filing in Oct 2020
ITab	• **Bi specific antibody** platform for immune oncology • **Multiple assets in pre-IND and Phase I** for China and global development in **liquid and solid tumor** types	• **China Phase I trial** for CD19/CD3 antibody to treat B cell malignancies FPFV Sep 2019	• China Phase I trial for CD19/CD3 antibody to treat B cell malignancies completion in 2021
F-652	• Dimeric rh**IL-22** fusion protein to treat multiple inflammatory disorders • Active development programs in **AH, aGvHD, COVID-19, and AP** • Potential **FIC, orphan drug and Breakthrough** status	• **ODD for aGvHD** granted in Oct 2019. aGVHD resultpresented at TCT Feb. 2020 and EBMT Mar. 2020 • **AH Phase II Study** published in Hepatology in Nov 2019 • **COVID-19 pre-IND** approved May 2020	• **aGvHD EMA OD submission** May 22, **PRIME** June 4. **Phase 2b-3** in plan • **AH IND submission** May 2020. **FDA BTD submission** in preparation. Phase 2b in plan • **COVID-19 IND submission**

ITab™,1 platform generates unique CD3-activating multi-specific antibodies to address unmet needs in the Immuno-Oncology space

Tumor affinity

Mono/bivalent binding in bi- and tri-specific formats

- Strong and targeted tumor affinity
- Accumulation of activated T cells within tumors

Safety

2nd generation CD3 engaged with selective T cell activation

- Low risk of cytokine release syndrome
- Manageable safety window

Stability

CHO2 expression manufacturing

- Commercial scale manufacturing in 30L bioreactors
- High stability with low aggregation

Asset	A-337	A-319	A-329
Target	EpCam (Bivalent)	CD19 (Monovalent)	CD19 (Bivalent)
Indication	Solid Tumors	B cell malignancies	Non-Hodgkin's Lymphoma
Status	Ph I (Australia)	Ph I (China) FPFV3 Sep 2019	IND ready

Notes: 1) ImmunoTherapy Antibodies; 2) Chinese hamster ovary; 3) First Patient First Visit

F-627 is a novel long-acting G-CSF[1] with completed China and global Phase III trials for CIN[2] with US, EU and China filings in 2020



- Novel dimeric Fc fusion protein structure
- Avoids PEGylation used in other long-acting G-CSFs

Advantageous combination of efficacy and improved safety

- F-627 combines the strength of Neupogen with convenience of Neulasta
  - The only novel long-acting G-CSF with data against both pegfilgrastim and filgrastim
- F-627's non-pegylated formulation reduces the possibility of severe allergic reactions caused by the pegylation[1]
- Robust clinical development program incl. placebo, Neupogen and Neulasta-controlled Phase III trials.
- Global commercial partnering process for US, Europe and Japan.

Notes: 1) Granulocyte-Colony Stimulating Factor; 2) Chemotherapy Induced Neutropenia

F-652 is a dimeric recombinant human IL-22 fusion protein with unique potential to treat multiple inflammatory disorders

Endogenous IL-22 plays a pivotal role in tissue protection and repair during injuries or infections

F-652 programs ongoing for treatment of Alcoholic Hepatitis, GvHD1 and Acute Pancreatitis



Epidermal keratinocytes
- Increased anti-bacterial defense
- Retarded differentiation and cornification

Intestinal epithelial cells
- Increased anti-bacterial defense
- Elevated mucus production

Respiratory epithelial cells
- Better anti-bacterial defense
- Enhanced proliferation

Hepatocytes
- Increased acute-phase protein production
- Elevated liver progenitor cell proliferation

Synovial fibroblasts
- Elevated RANKL expression
- Increased production of monocyte-attracting chemokines

Pancreatic cells
- Inhibition of autophagy
- Enhanced islet cell proliferation

First-in-class approach to treat inflammatory disorders

- Traditional therapies mediate immune system
- IL-22 addresses impacted tissues by **eliciting host defense against infection, and tissue repair to maintain tissue homeostasis**

Strong scientific position

- Published discoveries in ***Nature Med. Science*** **(2008),** ***Immunity*** **(2012) and** ***Nature*** **(2015)**
- **Ph IIa for Alcoholic Hepatitis completed** and filing for **breakthrough status** underway
- **Ph IIa for Acute GvHD1** ongoing and received **orphan drug designation** in Oct 2019
- **Strong scientific position**

Market potential[2]

- **Alcoholic Hepatitis 10yr cumulative sales projection > US$4b**

Notes: 1) Graft vs Host Disease; 2) Alcoholic Hepatitis for US, EU-5 and JP included. GvHD and Acute Pancreatitis not included

03

Product portfolio:

Anti-Infectives

Registered products

Active Pharmaceutical Ingredient	Dosage Form	Volume/ strength	MA Holder	Country of MA
Amikacin	Ampoule	500mg /2ml	fisiopharma	Italy
Bupivacaine[1]	Ampoule	Multiple		
Cefotaxime	Vial, Ampoule	Multiple		
Chloramphenicol sodium succinate	Vial, Ampoule	1g/10 ml solvent		
Dobutamine[1]	Vial	250mg /20ml		
Erythromycin lactobionate	Vial, Ampoule	Multiple		
Fructose-1,6-Diphosphate Trisodium Salt	Vial	10g/100ml solvent		
Furosemide	Ampoule	20mg/2 ml		
Gentamicin sulphate	Ampoule	Multiple		
Heparin	Vial, Ampoule	Multiple		
Lidocaine hydrochloride[1]	Ampoule	Multiple		
Megestrol acetate	Tablets	160mg		
Midazolam HCl	Ampoule	Multiple		
Pamidronate	Vial	Multiple		
Piperacillin	Vial, Ampoule	Multiple		
Piperacillin/tazobactam	Vial	Multiple		
Potassium aspartate	Ampoule	Multiple		
Tobramycin	Ampoule	Multiple		
Triamcinolone acetonide[1]	Vial	Multiple		
Vancomycin hydrochloride	Vial	Multiple		

[1] Bupivacaine, Dobutamine, Lidocaine hydrochloride and Triamcinolone acetonide are not available in US

Registered products with Fisiopharma as Contract Manufacturing Organization (CMO)

Active Pharmaceutical Ingredient	Dosage Form	Volume/ strength	MA Holder	Country of MA
Amiodarone	Ampoule	150mg/3ml	Third Party	Canada
Chloramphenicol	Vial	1000mg	Co-owned	Israel Canada Australia Netherlands
Cyanocobalamine	Vial	10ml, 30ml	Third Party	Canada
Dexamethasone	Vial	20mg/5ml	Third Party	Canada
Fructose biphosphate disodium salt	Vial	5g	Third Party	Vietnam

CMO = Contract Manufacturing Organization

Products under development

Active Pharmaceutical Ingredient	Dosage Form	Volume/ strength	Dossier Owner	Dossier Availability	Excluded Territory
Sugammadex	Vial	2, 5 ml	Fisiopharma	2020	China
Triamcinolone Acetonide (new formulation)	Vial	1, 5, 10 ml	Third Party	2019	US
Propofol (new formulation with aqueous base – low contamination risk and less pain)	Vial	20, 50, 100 ml	Third Party	2020	N/A
Iloprost	Ampoule	2 ml	Third Party	2019	China

Why partner with **Scigen?**

Who are we?

- We believe in delivering solutions that matter to the people of today and innovating for the people of tomorrow.
- To us, it is more than a business - it is a mission.

What do we do?

- We combine a specialty pharmaceutical business with a leading biologics biotechnology engine.
- We partner to bring the best drugs we can find to the patients who need it most.

How do we do it?

- Our R&D efforts aim to deliver better patient outcomes through better science.
- We understand that humility and service matter as it is not about us, it is about making patients' lives better.

Contact us today for more information

Reach out to our representative
for a deeper conversation today

Ba The Nguyen

Country Manager Vietnam
bathe.nguyen@scigen.com.sg

Deepak Kadecha

Regional Head - Middle East, Africa & India
deepak.kadecha@scigen.com.sg

Bharath Jayaraman

Head of Commercial Markets APMA
bharath.jayaraman@scigen.com.sg

Grzegorz Ornowski

Region Head - Europe & CIS
grzegorz.ornowski@scigen.com.sg

Churairat Erstmann

Commercial Manager Thailand
churairat.erstmann@scigen.com.sg

Rubens Paulella

Region Head - Latin America
rubens.paulella@scigen.com.sg

SciGen Pte Ltd

150 Beach Road,
#32-05/08 Gateway West,
Singapore 189720

Tel	+65 6779 6638
Fax	+65 6779 3784